"Safety and Efficacy of Coagulation Factor VIIa (Recombinant) when Administered as I.V. Bolus or I.V. Continuous Infusion to Hemophilia A or B Patients With Inhibitors Undergoing Elective Major Surgical Procedures. DOUBLE

According to an abstract submitted by the authors to the conference Hemophilia Care in the New Millennium: An International Symposium in Honor of Harold R. Roberts, M.D., held April 8-10, 1999, at the University of North Carolina, Chapel Hill, North Carolina, "Treatment of patients with hemophilia and inhibitors or acquired inhibitors against Factor VIII or IX represent a major challenge to clinicians. Activated recombinant coagulation factor VII (rFVIIa) is a newly developed approach to the treatment of these patients. An ongoing open label, randomized trial in the US is comparing safety and efficacy of rFVIIa administered by continuous infusion or by bolus injection to patients with...

Want to see the full article?

• Purchase this article for only $3.00